Loading clinical trials...
Loading clinical trials...
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Conditions
Interventions
BMX-001
Radiation Therapy
+1 more
Locations
9
United States
University of Alabama- Birmingham
Birmingham, Alabama, United States
University of California San Francisco
San Francisco, California, United States
University of Kentucky
Lexington, Kentucky, United States
St. Luke's Hospital
Kansas City, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Duke Cancer Institute
Durham, North Carolina, United States
Start Date
September 25, 2018
Primary Completion Date
August 17, 2023
Completion Date
December 31, 2024
Last Updated
June 8, 2025
NCT05969860
NCT03340506
NCT02800486
NCT05278208
NCT05789394
NCT06934889
Lead Sponsor
BioMimetix JV, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions